Research programme: human papillomavirus vaccines - MediGene AG/Johns Hopkins University/Pennsylvania State University
Alternative Names: AAVLP technology - MediGene; AAVLP vaccine carrying HPV L2 epitopes - MediGene AGLatest Information Update: 23 Feb 2023
Price :
$50 *
At a glance
- Originator MediGene AG
- Developer Johns Hopkins University; MediGene AG; The Pennsylvania State University
- Class Cancer vaccines; Synthetic vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer; Human papillomavirus infections
Most Recent Events
- 23 Feb 2023 Discontinued - Preclinical for Cancer (Prevention) in USA (Parenteral)
- 23 Feb 2023 Discontinued - Preclinical for Human papillomavirus infections in USA (Parenteral)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Cancer(Prevention) in USA (Parenteral)